Evidence · condition
Multiple sclerosis (MS)
LAST REVIEWED 2026-09-22 · CASE REPORT / NARRATIVE · COI AWARENESS · NOT PROVEN
Ibogaine is not an established MS disease-modifying or curative therapy. Public literature includes Ambio-affiliated case neuroimaging reports and a 2026 narrative review discussing remyelination hypotheses — still far from confirmatory evidence.
Is ibogaine an MS treatment?
Not established. Remyelination marketing in media is not an evidence upgrade.
- Evidence level
- Case report + narrative review — not confirmatory trials
- Conflicts of interest
- Clinic-linked authorship must be labeled; commercial proximity affects claim weight
- What is not proven
- Ibogaine as a general MS disease-modifying or curative therapy
- Safety
- Cardiac / QTc literacy still applies
- Self-treatment
- DIY refusal
What exists (source-labeled)
Case report with neuroimaging (COI: Ambio-funded / clinic-affiliated)
Chen, Inzunza Domínguez, Valle Uzeta, Pushparaj, Dickinson, 2025. “Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.” Frontiers in Immunology. PMID 39981248, DOI 10.3389/fimmu.2025.1535782. PubMed COI statement: authors affiliated with / shareholders of Ambio Life Sciences; study funded by Ambio with funder involvement in design, data collection/analysis, decision to publish, and manuscript preparation. Label: n-of-few case report + major COI.
Narrative / hypothesis review (not a trial)
Calvey et al., 2026. “Neurorestorative properties of ibogaine: linking multi-receptor affinities to remyelination and metabolic restoration.” Acta Neuropsychiatrica. PMID 41679899, DOI 10.1017/neu.2026.10059. Discusses observational linkages and putative remyelination/metabolic mechanisms; does not establish MS efficacy. Author COI disclosures include psychedelic-industry consulting for some co-authors (see PubMed COI statement).
What does not exist
- Adequately powered controlled trials of ibogaine for MS with independent adjudication.
- Regulatory approval of ibogaine as an MS therapy.
- Any basis for “cures MS” / miracle remyelination language in IbogaBase voice.
How to weigh clinic-adjacent MS claims
Ask who funded the work, who employed the authors, whether imaging/outcomes were independently adjudicated, and whether adverse events are reported with denominators. See Clinic claims and adverse events and clinic success-rate claim check. Compare density to OUD and TBI — still limited, but denser than MS on this site.
FAQ
Can I use ibogaine for MS at home?
IbogaBase will not help with self-treatment. See the refusal page.
Does lesion shrinkage in two patients prove benefit?
No. Case reports generate questions; they do not establish efficacy, especially under funder-involved COI.